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Abstract: EBNA1, a nuclear protein expressed in all EBV-associated neoplasms is 
indispensable for the maintenance of the viral episomes in latently infected cells. EBNA1 
may induce genetic alterations by upregulating cellular recombinases, production of 
reactive oxygen species (ROS) and affecting p53 levels and function. All these changes 
may contribute to tumorigenesis. In this overview we focus, however, on the epigenetic 
alterations elicited by EBNA1 by drawing a parallel between EBNA1 and the FoxA family 
of pioneer transcription factors. Both EBNA1 and FoxA induce local DNA demethylation, 
nucleosome destabilization and bind to mitotic chromosomes. Local DNA demethylation 
and nucleosome rearrangement mark active promoters and enhancers. In addition, EBNA1 
and FoxA, when associated with mitotic chromatin may “bookmark” active genes and 
ensure their reactivation in postmitotic cells (epigenetic memory). We speculate that DNA 
looping induced by EBNA1-EBNA1 interactions may reorganize the cellular genome. 
Such chromatin loops, sustained in mitotic chromatin similarly to the long-distance 
interactions mediated by the insulator protein CTCF, may also mediate the epigenetic 
inheritance of gene expression patterns. We suggest that EBNA1 has the potential to 
induce patho-epigenetic alterations contributing to tumorigenesis. 
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1. Introduction 
Epstein-Barr virus (EBV), a herpesvirus widespread in human populations, replicates in 
oropharyngeal epithelial cells and establishes lifelong latent infection in resting memory B cells. 
Although the primary infection is usually inapparent, the association of EBV with a series of 
lymphomas and carcinomas and its potential role in the pathogenesis of certain autoimmune diseases 
resulted in a detailed description of the viral latency products and their host cell dependent expression 
patterns (EBV latency types) (reviewed in [1,2]). EBV-encoded nuclear proteins (EBNAs), 
transmembrane proteins (latent membrane proteins, LMPs) and non-translated RNAs (EBERs and 
microRNAs) were implicated both in tumorigenesis and in vitro immortalization of human B 
lymphocytes. The nuclear antigen EBNA1 is indispensable for the maintenance of viral latency due to 
its involvement in the duplication, partitioning and maintenance of the viral episomes [3]. Most 
research focused on how EBNA1 attracts the cellular replication machinery to oriP, the latent origin of 
replication, and how EBNA1 mediates nonrandom segregation of the viral episomes. Thus, EBNA1 
was not considered to be a typical viral oncoprotein that alters the behaviour of its target cells: such a 
role was usually attributed to other EBV latency products (LMP1, EBNA2, EBERs, microRNAs). The 
contribution of EBNA1 to neoplastic development was thought to be the maintenance of the viral 
episomes within the cells, permitting thereby the expression of latent proteins and RNAs directly 
involved in oncogenesis. Unexpectedly, however, certain observations suggested a more direct role for 
EBNA1 in the initiation and progression of malignant neoplasms and pointed to the potential 
importance of EBNA1-induced genetic alterations in tumorigenesis. Srinivas and Sixbey demonstrated 
that EBNA1 could induce the expression of the V(D)J recombinase-activating genes RAG1 and RAG2 
in an EBV negative Burkitt’s lymphoma (BL) cell line [4]. Because RAG1 and RAG2 were implicated 
in eliciting chromosome translocations in B-cell neoplasms, these data suggested that EBNA1 may 
promote genomic instability resulting in cytogenetic alterations and lymphomagenesis. In addition, 
EBNA1 up-regulated NOX2, the catalytic subunit of the NADPH oxidase involved in the production 
of reactive oxygen species (ROS), possibly through an EBNA1-binding site the within the  
NOX2-promoter, and induced chromosomal alterations and DNA double-strand breaks in vitro [5,6]. 
Sivachandran et al. speculated that a decreased apoptotic response and impaired DNA repair 
associated with the downregulation of p53 levels by EBNA1 [7] as well as impaired acetylation of p53 
due to the disruption of promyelocytic leukemia nuclear bodies (PML NBs) by EBNA1 also contribute 
to the development of EBV-associated neoplasms [8,9]. 
Recently, the genetic theory of carcinogenesis that dominated the field of cancer research for a long 
time was supplemented with epigenetic models, and it was observed that viral oncoproteins regularly 
cause epigenetic dysregulation in neoplastic cells (reviewed in [10,11]). In this review we focus on the 
epigenetic changes elicited by EBNA1 and compare them to the exciting new observations as to the 
epigenetic marks left on the chromatin by pioneer transcription factors. 
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2. Pioneer Transcription factors: The FoxA Family 
In mammals, pioneer transcription factors control organogenesis of liver, lung, pancreas, prostate 
and midbrain [12,13]. These DNA binding proteins may enable cellular reprogramming by binding to 
enhancer regions even in highly compacted chromatin regions [14] (reviewed in [15]). 
FoxA proteins, the prototype pioneer factors that belong to the forkhead box (Fox) family are 
thought to open chromatin through replacement of linker histone H1, a structurally similar winged 
helix domain protein [14,16] (reviewed in [17,18]). Due to their high nucleosome-binding affinity, 
FoxA1 and FoxA2 move more slowly in nuclei than other classes of transcription factors (c-Myc, 
GATA-4, NF-1 and HMGB1) [19]. FoxA binding increases the accessibility of other transcription 
factors to the neighboring regulatory sequences that flank FoxA recognition sites. In addition, binding 
of FoxA is associated with the maintenance or creation of an epigenetic mark, local CpG 
hypomethylation as well [12]. This means that FoxA binding either prevents de novo cytosine 
methylation at CpG dinucleotides recognized by DNA methyltransferases or induces active or passive 
demethylation of methylcytosines within or in the vicinity of its recognition sequence. Sérandour et al. 
argued that in a neural differentiation model the establishment of transcriptional competence at 
FOXA1-dependent enhancers is associated with an epigenetic switch that involves both DNA 
demethylation and induction of histone H3 mono- and dimethylation at lysine 4 (H3K4me1, 
H3K4me2) [20]. Because retinoic acid induced differentiation of P19 embryonal carcinoma cells does 
not favour cell division, one may speculate that FoxA1 binding probably induced active, enzymatic 
demethylation of certain methylcytosine residues in the vicinity of its recognition sequences. Passive 
demethylation, based on the inhibition of the maintenance DNA methyltransferase DNMT1 during the 
S phase of the cell cycle depends on cell proliferation and seems to be a less plausible mechanism in 
differentiating cells. The capacity to demethylate in vitro pre-methylated plasmids carrying cloned 
enhancer sequences depends on the cell type. Such enhancers either remain silent and methylated in 
differentiated cells unless the repressive Mi-2/NurD chromatin remodeling complex is depleted, or, as 
in certain embryonic stem cells and induced pluripotent stem cells, they may undergo demethylation 
despite the absence of active transcription [21,22]. 
In embryonic stem cells silent tissue-specific enhancers were marked by windows of unmethylated 
CpG dinucleotides, some of them located within pioneer factor binding sites [21]. These findings were 
in harmony with the idea that in embryonic stem cells a permissive chromatin structure is assembled at 
the enhancers of inactive tissue-specific promoters. Such preexisting protein-DNA interactions or 
„enhancer marks” may prevent the formation of a repressive chromatin structure during differentiation 
and permit the activation of silent promoters at a subsequent developmental stage in response to  
tissue-inductive signals, steroid hormones, other stimuli or pathological alterations (metaplasia, 
tumorigenesis) [12,21,23,24]. It is worthy to note that FoxA1, in concert with the transcription factors 
MYBL2 and CREB1, also induced histone H3 acetylation, a histone modification characteristic for 
active chromatin, and facilitates nucleosome disruption in castration-resistant prostate cancer [25].  
The long terminal repeat sequence of mouse mammary tumor virus (MMTV LTR) also carries 
binding sites for FoxA, and Holmqvist et al. observed that attachment of FoxA1 resulted in 
nucleosome rearrangement and affected the activity of the MMTV promoter [26]. Furthermore, 
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forkhead box proteins FoxO1 and FoxA (also called hepatocyte nuclear factor 3, HNF3), are involved 
in the regulation of hepatitis B virus transcription in infected liver cells [27] (reviewed in [28]). 
3. “Bookmarking” the Mitotic Chromatin: A Novel form of Epigenetic Memory 
Both FoxA1 as well as FoxI1, another member of the Fox family expressed in zebrafish, remain 
bound to chromatin even in mitotic chromosomes [12,29], suggesting that their binding to DNA might 
serve as an independent epigenetic mark. Thus, similarly to the complexes of Polycomb and Trithorax 
family proteins and DNA methylation [30], chromatin-bound pioneer factors may also ensure the 
inheritance of gene expression patterns. Indeed, Zaret et al. speculated that retaining of a pioneer factor 
(so called „bookmarking” protein) in mitotic chromatin may help to “remember” postmitotic daughter 
cells the gene expression pattern of the parental cell by facilitating a more rapid or synchronous 
activation of the FoxA target genes following chromosome decondensation [12]. The concept of 
bookmarking genes for activation in condensed mitotic chromosomes was introduced by John and 
Workman [31]. It turned to be that bookmarking is mediated by protein-DNA interactions that alter 
chromatin structure. Xing et al. demonstrated that binding of the transcription factor HSF2 (heat shock 
factor 2) to the promoter region of the hsp70i gene in mitotic cells prevents compaction by the 
recruitment of protein phosphatase 2A (PP2A) that inactivates condensin complexes [32] (reviewed  
in [33]). During mitosis, HSF2 bookmarks the promoters of other heat shock genes (hsp90, hsp27) and 
the c-fos proto-oncogene promoter, too [34]. Similarly to HSF2, TBP (TATA-binding protein) was 
found to be retained at many chromosomal sites during mitosis. TBP recruited PP2A and interacted 
with condensin, suggesting that it may contribute to gene bookmarking [35] (reviewed in [36]). 
Hepatocyte nuclear factor-1β (HNF-1β), a transcription factor deleted in polycystic kidney disease, 
remains associated with mitotic chromosomes as well [37]. HNF-1β was suggested to act as a 
bookmarking factor reopening the chromatin of its target genes after mitotic silencing [37]. Genes 
highly transcribed during interphase retained the Trithorax protein MLL (mixed lineage leukemia) at 
their promoters during mitosis [38]. This observation implies that mitotic bookmarking contributes to 
gene regulation by Trithorax complexes by accelerating transcriptional reactivation following mitosis. 
Because MLL is a histone methyltransferase which catalyzes H3K4 tri-methylation, these data are 
consistent with the finding that H3K4me3, a mark of euchromatin in the G1 phase of the cell cycle, 
remained associated with the condensed chromatin of mitotic chromosomes as well [39].  
4. “Bookmarking” of Active Promoters by a Variant Histone and Altered Nucleosome Occupancy 
Recently, the histone variant H2A.Z, localized in a hyperacetylated form near the transcriptional 
start site (TSS) of active genes in interphase cells, was found to be associated, although in a 
deacetylated form, with mitotic chromosomes in chicken cells [40] and M phase chromatin of human 
cells [41]. Kelly et al. suggested that H2A.Z may mark certain gene sets for rapid re-expression 
following mitotic exit and destabilize nucleosomes located in the vicinity of transcriptional start sites, 
allowing nucleosome sliding either toward the TSS, that blocks transcription factor and RNA 
polymerase II binding during mitosis, or away from the TSS that may permit promoter activation after 
chromosome decondensation [41]. Kelly and Jones speculated that nucleosomal rearrangement 
combined with the H2A.Z mark and modifications of histone H3 (H3K4me3, and phosphorylation at 
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serine 10, H3S10P) allows the nucleosome to maintain an active configuration in the vicinity of silent 
promoters in mitotic chromatin and permits a rapid reactivation of the marked promoters following 
mitotic exit [42]. Thus, marking of active promoters by altered nucleosome occupancy at the TSS may 
serve as a novel, general epigenetic mechanism ensuring gene reactivation and restoration of cell type 
specific gene expression patterns in the daughter cells following mitosis.  
5. Factors other than FoxA: Association with Mitotic Chromosomes 
Factors repressing transcription may also associate with mitotic chromosomes. Runx2, a  
runt-related transcription factor, acts as a repressor of RNA polymerase I mediated ribosomal RNA 
(rRNA) synthesis, and it is retained associated with rRNA genes at nucleolar organizing regions within 
the condensed mitotic chromosomes [43]. It is noteworthy that Runx2, a regulator of osteogenesis, also 
associated with the RNA polymerase II transcribed promoters of its target genes in mitotic 
chromosomes and established a transcriptionally poised chromatin structure at the target gene 
promoters [44]. This silent chromatin thought to be ready for transcription contained a basal level of 
acetylated histone H4 and a constitutively high level of histone H3 dimethylated at lysine 4. One may 
wonder, however, whether–in mitotic chromosomes–Runx2 also remains associated with the promoters 
of RNA polymerase II transcribed genes that happen to be switched off by Runx2 binding [45]. This 
possibility remains to be investigated. In a recent live cell imaging study, Pockwinse et al. 
demonstrated that the binding affinity of Runx2 apparently increased as chromosomes condensed, 
possibly due to phosphorylation during mitosis [46]. Such a mechanism may affect Runx2 proteins 
both in transcriptionally active or repressive chromatin.  
PU.1, a transcription factor interacting with lineage-specific enhancers in B cells and myeloid cells 
appears to maintain a high level of histone H3 lysine 4 mono-methylation (H3K4me1) at its targets and 
cooperates with stimulus-responsive transcription factors in enhancer activation [47,48]. PU.1 belongs 
to the ets family of regulatory proteins and the structure of its conserved ETS DNA binding domain is 
similar to the build up of “winged” helix-turn-helix proteins [49]. Whether PU.1 can replace histone 
H1 at enhancers, similarly to FoxA, remains to be clarified. It is worthy to note, however, that in 
addition to establishing a permissive chromatin structure at myeloid or B cell specific genes, PU.1 may 
also create a repressive chromatin structure to extinguish the activity of genes involved in erythroid 
differentiation. Downregulation of the alternative gene expression program is achieved by binding of 
PU.1 to GATA-1, a pioneer factor indispensable for erythroid differentiation. PU.1 blocks GATA-1 
DNA binding by interacting with the C-terminal zinc finger of GATA-1 [50]. In addition, PU.1 
organizes a repressor protein complex at GATA-1 regulated promoters [51]. The repressive chromatin 
contains heterochromatin protein 1 (HP1) and modified histone H3 methylated at lysine-9.  
PBX1 (pre-B-cell leukemia homeobox 1), a homeodomain protein, interacts with and affects the 
DNA-binding specificity and affinity of Hox (homeotic) proteins which are governing the choice 
between alternative developmental pathways [52,53]. Recently PBX1, involved in diverse 
developmental processes [54], was characterized as a novel pioneer factor that may open chromatin at 
specific genomic locations and recruit estrogen receptor alpha (ERα) to estrogen responsive genes in 
breast cancer cells [55]. Magnani et al. argued that a specific epigenetic signature, histone H3  
di-methylated at lysine 4 (H3K4me2), is preferentially recognized by PBX1. It is worthy to note that 
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also the pioneer factor FoxA1 recruits ERα to H3K4me2-enriched regulatory elements in breast cancer 
cells [56], but only PBX1 expression correlated with metastasis formation and development of 
resistance to endocrine therapies in patients with ERα positive breast cancer [55].  
6. Chromatin Loops Maintained in Mitotic Chromatin 
In addition to pioneer factors, CTCF (CCCTC-binding factor), an insulator protein separating 
chromatin domains and mediating higher order chromatin interactions (looping) is also bound to 
mitotic chromatin [57]. Burke et al. suggested that CTCF binding may represent a novel form of 
epigenetic memory, because it maintains distinct long-distance interactions in mitotic chromosomes 
that may facilitate the reestablishment of other higher order interactions lost in mitotic chromatin, after 
cell division [57].  
7. EBNA1: Anchoring of EBV Episomes and Looping DNA 
Epstein-Barr virus (EBV), a human gammaherpesvirus, is associated with a series of malignant 
tumors (reviewed in [1]). EBV replicates in the epithelial and lymphoid cells of the oropharynx and 
establishes latent infection in memory B cells. The lymphomas and carcinomas associated with EBV 
also carry latent viral episomes expressing only a subset of the viral genes. The only EBV-encoded 
nuclear antigen invariably present in EBV-associated neoplasms is EBNA1 that binds to oriP, the 
latent origin of EBV replication and tethers the viral episomes to the nuclear matrix in interphase cells 
and to metaphase chromosomes during mitosis (reviewed in [58]).  
Episomal maintenance in cells carrying latent EBV genomes is achieved by EBNA1 that binds 
directly to multiple sequence specific binding sites within oriP and binds directly or indirectly to  
AT-rich DNA sequences of host cell chromosomes [59–61]. Whereas EBNA1 homodimers bind to 
oriP via the carboxy-terminal DNA-binding domain that contacts both the major and the minor groove 
of the DNA [62,63], association with cellular chromosomes is mediated by three amino-terminal 
EBNA1 domains [64], two of them containing repeats of glycine and arginine (GR repeats), termed 
AT hooks [60]. The second GR-repeat is mostly responsible for chromosomal attachment [61,65,66]. 
GR repeat 2 also interacts with the cellular protein EBP2 (EBNA1 binding protein 2) that ensures a 
tight chromosomal association and mitotic segregation of EBV genomes [61,67,68]. Based on 
experiments with oriP containing plasmids, Sears et al. argued that metaphase chromosome tethering 
of the episomes by EBNA1 may create an opportunity for the cellular origin recognition complex 
(ORC), located at AT-rich DNA regions of cellular DNA, to interact with and be loaded onto  
oriP [60]. Replacement of the basic chromosome-associating domains of EBNA1 by either amino 
acids 1-90 of the high-mobility-group protein HMG-I, full-length HMG1a, or substituting them with 
the basic protein histone H1 resulted in hybrid proteins enabling the EBNA1 C-terminus to bind to 
mitotic chromosomes [59,69].  
EBNA1 not only governs the replication and segregation of the viral episomes, but by binding to a 
repetitive sequence (family of repeats, FR) within oriP it also transactivates the latent EBV promoters 
Cp and LMP1p [70,71], presumably via one of its looping/linking domains (residues 325–376; [72–74]. 
The EBNA1 looping/linking/transactivating domain contributes to the maintenance of the episomal 
EBV genomes in latently infected cells (reviewed in [3]). Association between the looping/linking 
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domains of EBNA1 dimers or monomers bound to distant regions may result in looping out of the 
intervening DNA [73,75–77]. We suggest that certain higher order chromatin structures (loops) created 
by EBNA1-EBNA1 interactions may be sustained in mitotic chromosomes and form the basis of a 
novel type of epigenetic memory that involves a viral protein. Thus, EBNA1 bound to its recognition 
sequences in the host cell genome may alter the architecture and interactions of certain genomic 
regions and ensure the epigenetic inheritance of such a novel higher order structure from cell generation 
to cell generation. 
8. EBNA1: Marking Cellular Genes 
In addition to interacting with EBV genomes, EBNA1 also binds diverse sequence motifs close to 
the transcriptional start sites of a series of cellular genes in Raji Burkitt lymphoma (BL) cells [78]. 
EBNA1 binding sites were found in LINE1 retrotransposons as well. Lu et al. observed that the 
consensus sequence for cellular EBNA1 binding sites differs from that of the binding sites within the 
EBV genome, located at FR and the dyad symmetry (DS) element within oriP, and at the Q promoter 
(Qp). This suggests that the cellular sites may bind EBNA1 indirectly [78]. Transfection of the EBNA1 
gene into the EBV negative BL line BJAB and the epithelial cell line 293 also revealed a DNA motif at 
EBNA1 regulated cellular promoters that differed from the viral binding sites [79]. Several  
EBNA1-binding sites were found in the cellular genome of 721 lymphoblastoid cells and in the viral 
genomes of KSHV and Herpesvirus papio. A rep*-like sequence from the Herpesvirus papio genome 
which binds EBNA1 functioned as an origin of DNA replication in Raji cells [80]. The consensus 
motif for EBNA1 binding defined by Dresang et al. was similar to Motif 2 found by Lu et al. [78,80]. 
The partial overlap and differences between the sequence motifs defined by these three studies [78–80] 
may be due to the use of different cell lines. An additional computational approach identified a set of 
40 FR-like sequences within the human genome which may specifically bind EBNA1. The functional 
significance of these potential EBNA1 binding sites needs to be further explored [81]. An EBNA1 
deletion mutant leaving both GR repeats intact, but deleting the small unique region 1 (UR1) just next 
to GR repeat 1, defined a novel transcriptional transactivation domain within EBNA1 [58]. ΔUR1 
mutant viruses segregated the plasmid maintenance and transcriptional activation functions of EBNA1. 
While supporting DNA binding and plasmid maintenance, the UR1 deletion mutant was not able to 
transcriptionally activate the C-promoter anymore. Thus, the Wp to Cp switch did not occur in cells 
infected with the respective ΔUR1 viruses, and the infected cells were not transformed, but ceased 
growing shortly after infection [82]. The UR1 peptide, which is conserved among EBNA1 orthologs of 
other -herpesviruses and is also found in the catalytic domains of some DNA polymerase δ enzymes, 
binds and coordinates Zn
2+
 ions and contributes to EBNA1 dimerization. Furthermore, the UR1 
transactivation function of EBNA1 on Cp is sensitive to oxidation levels and works best under hypoxic 
conditions [83]. Whether the UR1 peptide plays a role in activating cellular genes needs further studies. 
9. EBNA1: Displacement of Nucleosomes and Induction of Site-Specific Demethylation 
In cells carrying latent EBV episomes, viral DNA synthesis is initiated once per cell cycle typically 
at the DS element containing four EBNA1 binding sites (reviewed in [3]). EBNA1 is capable of 
interacting with the DS element, even if it is assembled into a nucleosome core particle, and EBNA1 
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binding results in nuclesosome destabilization and displacement [84]. Access to the EBNA1 binding 
sites at DS and FR by EBNA1 does not require ATP-dependent chromatin-remodeling factors [85]. In 
contrast, the nucleosomes flanking DS undergo chromatin remodeling mediated by the SNF2h (sucrose 
nonfermenting 2 homolog) ATPase, in parallel with histone deacetylation. This event happens at the 
G1/S-border of the cell cycle after the cellular minichromosome maintenance (MCM) helicase 
complex is loaded to the four EBNA1 homodimers of the DS element associated with the origin 
recognition complex (ORC), another component of the cellular replicative machinery [86]. Binding of 
parts of the MCM complex after mitosis licences oriP firing in the ensuing S phase [87] (reviewed  
in [3]). Binding of EBNA1 to its recognition sites was stimulated by the recruitment of the cellular 
deubiquitylating enzyme USP7 which cleaves monoubiquitin from histone H2B. Thus, by recruiting 
USP7, EBNA changes the histone ubiquitylation state of the chromatin at oriP [88]. 
EBNA1 is capable of binding to both unmethylated and methylated oriP sequences. Attachment of 
EBNA1 to its binding sites carrying methylated CpG dinucleotides results in a simultaneous  
site-specific demethylation both in FR and DS, provided that the oriP sequences are replicating [89]. 
The site-specific demethylation affects only methylcytosines located within EBNA1 binding sites: 
adjacent methylcytosines in the region, situated near to but outside EBNA1 recognition sequences 
remain methylated. Thus, EBNA1 binding can specify demethylation sites. Hsieh suggested that 
EBNA1 binding interferes with the function of the maintenance DNA methyltransferase (DNMT1) 
that copies the DNA methylation pattern of the parental strand to the daughter strand after DNA 
replication, resulting in passive demethylation of the first DNA strand at oriP, whereas active 
demethylation, mediated by a demethylase enzyme recruited to hemimethylated DNA may occur on 
the second strand of oriP [89]. High affinity protein binding to a methylated DNA sequence located 
outside of an origin of DNA replication may also result in site-specific demethylation [90].  
10. EBNA1: Reprogramming the Epigenome? 
Binding of EBNA1 to metaphase chromosomes [91–93] and cellular promoters [78,79] raises the 
possibility that EBNA1 acts like a bookmarking protein that affects the expression of its cellular target 
genes in a heritable manner. We suggest that epigenetic inheritance of the EBNA1 dysregulated 
cellular gene expression pattern may be ensured by local demethylation and nucleosomal rearrangements 
induced by EBNA1 at its cellular binding sites (Table 1). Although EBNA1 is regularly expressed in 
EBV-associated neoplasms and in vitro transformed lymphoblastoid cell lines (LCLs), its role in 
oncogenesis was perceived mainly as an indirect one, i.e., maintenance of EBV episomes in the tumor 
cells, thereby permitting the expression of other viral proteins and non-translated viral RNAs that 
initiate and maintain malignant transformation. Expression of EBNA1 induced B cell neoplasia in 
certain transgenic mouse lines [94] but not in others [95,96]. In spite of these contradictory data, a role 
for EBNA1 as an oncoprotein in the generation of human neoplasms cannot be excluded at present. 
The functional similarities between the pioneer factor FoxA and EBNA1 (Table 1) as well as CTCF 
and EBNA1 suggest that EBNA1 is potentially capable for epigenetic reprogramming of EBV target 
cells which may result in tumorigenesis.  
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Table 1. Interactions of the pioneer transcription factor FoxA and the viral oncoprotein 
EBNA1 with epigenetic regulatory mechanisms. 
Epigenetic mechanism Phenomenon elicited by 
 FoxA EBNA1 
DNA methylation Demethylation Demethylation 
Histone acetylation Upregulation 
histone H3 
? 
Histone methylation ? ? 
Polycomb/Trithorax complexes ? ? 
Binding to mitotic chromosomes “Bookmarking”? “Bookmarking”? 
Nucleosome rearrangement Alteration of a hormone-dependent 
sub-nucleosome complex at the 
MMTV LTR 
Nucleosome destabilization at 
oriP of EBV episomes 
DNA looping ? EBNA1-EBNA1 binding may 
link distinct DNA regions in 
viral and cellular genomes 
(epigenetic memory?) 
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